GeoVax Labs’ (GOVX) “Buy” Rating Reiterated at D. Boral Capital

GeoVax Labs (NASDAQ:GOVX)‘s stock had its “buy” rating reissued by analysts at D. Boral Capital in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $18.00 price target on the stock.

GeoVax Labs Stock Performance

GOVX stock opened at $1.11 on Friday. GeoVax Labs has a one year low of $1.09 and a one year high of $11.18. The firm has a market cap of $10.47 million, a PE ratio of -0.20 and a beta of 3.06. The firm’s 50 day moving average price is $1.67 and its 200-day moving average price is $2.13.

GeoVax Labs (NASDAQ:GOVX) last posted its earnings results on Thursday, March 27th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.49. The company had revenue of $3.00 million during the quarter, compared to analyst estimates of $2.38 million. Equities research analysts predict that GeoVax Labs will post -4.49 EPS for the current fiscal year.

Institutional Trading of GeoVax Labs

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its position in shares of GeoVax Labs by 59.0% during the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after buying an additional 33,440 shares during the period. Citadel Advisors LLC acquired a new position in GeoVax Labs during the 4th quarter worth about $104,000. Virtu Financial LLC purchased a new position in GeoVax Labs during the 3rd quarter valued at about $97,000. Finally, Northern Trust Corp acquired a new position in GeoVax Labs in the 4th quarter valued at about $29,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.